36.28
+2.57%
Close of 2 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Indivior Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Indivior Pharmaceuticals is based in Rockville, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INDV. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.24bn and net income of $210.0m. At that date it held total assets of $1.20bn and shareholders' equity of −$98.0m.
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders.
Headquartered in the U.S. in Richmond, Virginia, Indivior and its portfolio of products is available primarily in the U.S. with additional products available in Canada, Australia, France, and Germany.
Our business was initially developed and managed as a separate division of Reckitt Benckiser Group PLC (“RB” and, together with its subsidiaries, the “RB Group”), a public limited company incorporated under the laws of England and Wales. Indivior PLC was incorporated on September 26, 2014, for the purpose of acquiring the specialty pharmaceutical business unit from RB (the “Demerger”). Following the Demerger, which was effective on December 23, 2014, Indivior PLC operated as a standalone business.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Dec 2014
- Employees
- 827
- Website
- indivior.com ↗
- Head office
- 10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD, VA, 23235
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. David WheadonNon-Executive Independent Chairman of the Board$76,500
- Mr. Joseph CiaffoniChief Executive Officer, Director, since 2024$4,000
- Ms. Angela Colon-MahoneyChief Human Resources Officer
- Mr. Christian HeidbrederChief Scientific Officer
- Ms. Cynthia CetaniChief Integrity and Compliance Officer
- Mr. Patrick BarryChief Commercial Officer
- Mr. Jeffrey BurrisChief Legal Officer
- Mr. Vishal KaliaChief Impact and Strategy Officer
- Mr. Hillel WestChief Manufacturing and Supply Officer
- Ms. Kathryn HudsonCompany Secretary
- Dr. Keith HumphreysNon-Executive Independent Director$131,400
- Mr. Stuart KingsleyIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 29
- Social
- 73
- Governance
- 56
- Direct emissions (scope 1)
- 4,573 t
- Energy emissions (scope 2)
- 2,196 t
- Value chain emissions (scope 3)
- 107,779 t
- Women in the workforce
- 51%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Indivior PLC develops buprenorphine-based drugs for opioid dependence treatment in the Health Care sector.
- Suboxone Film and Subutex Tablet are key products for opioid use disorder with strong market presence.
- RBP-6000 buprenorphine monthly depot targets opioid use disorder with innovative delivery system.
Weaknesses
- Indivior PLC has 824 full-time employees, which is relatively low for a pharmaceutical company.
- The company's focus on opioid dependence limits diversification across other health sectors.
- RBP-7000 risperidone monthly depot for schizophrenia is still in development phase.
Opportunities
- RBP-8000 cocaine esterase for cocaine intoxication presents new market opportunity in addiction treatment.
- The global opioid use disorder market continues to expand with increasing prevalence.
- Suboxone Film and Subutex Tablet can be expanded into new geographic markets like the United States.
Threats
- RBP-7000 risperidone monthly depot faces competition from established schizophrenia treatments.
- The opioid use disorder market is subject to regulatory changes affecting drug approvals.
- Suboxone Film and Subutex Tablet face potential generic competition in the future.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.